In the past year, three cardiovascular outcome trials were completed and showed that PCSK9 inhibitors significantly reduce the risk of major vascular events. Reassuringly, this benefit comes with no major offsetting adverse events, such as an excess of myalgias, elevation of hepatic aminotransferase...
Durairaj A, Sabates A, Nieves J, Moraes B, Baum S. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. Current treatment options in cardiovascular medicine. 2017 Aug:19(8):58. doi: 10.1007/s11936-017-0556-0. Epub...
et al. Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. AIDS 31, 2367–2376 (2017). CAS PubMed Google Scholar Schlegel, V. et al. Low PCSK9 levels are correlated with mortality in patients with end-...
Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and incident type 2 Diabetes: a systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care. American Diabetes Association Inc.; 2018. pp. 364–7. Goldman A, Raschi E, Cukierman-Yaffe T, Dankner R, Shou...
Purpose of reviewThis article reviews PCSK9 inhibitors (PCSK9i) with a focus on clinically relevant studies published in the last 18 months.Recent findingsPrespecified subgroup evaluations, secondary analyses, and open-label extension studies from the two landmark trials, FOURIER and ODYSSEY Outcomes,...
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients with atherosclerotic cardiova
In fact, one review of studies found that PCSK9 inhibitors slash LDL levels by an average of 47%. This protects your heart: The drugs were shown to reduce the risk of heart attack by 27%. What Makes Them Different? Statins work in a different way. One main way they work is to block...
Review Bookmark Cite as... There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience. Abstract Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of ...
This review examines the most recent evidence and future prospects for the use of PCSK9 inhibitors in the prevention of cardiovascular disease. Similar content being viewed by others Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia Article 23 November 2015 PCSK9 Inhibition...
PCSK9 inhibitors have significant effects on lowering LDL-cholesterol, reversing atherosclerotic plaques, and reducing the risk of cardiovascular events and have been approved by several lipid-lowering guidelines. This work was aimed to investigate the potential role of PCSK9 in the neck of AAA. We...